One of the most promising advances in the treatment of Polycythemia Vera comes from Janus kinase (JAK) inhibitors. These medications, particularly ruxolitinib and fedratinib, target the JAK2 gene mutation that drives the overproduction of red blood cells. In 2025, these inhibitors are beco